Literature DB >> 17664354

Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation.

André Tichelli1, Christoph Bucher, Alicia Rovó, Georg Stussi, Martin Stern, Michael Paulussen, Jörg Halter, Sandrine Meyer-Monard, Dominik Heim, Dimitrios A Tsakiris, Barbara Biedermann, Jakob R Passweg, Alois Gratwohl.   

Abstract

We assessed incidence and risk factors of cardiovascular events in 265 patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT) between 1980 and 2000 and who survived at least 2 years. Results were compared with a cohort of 145 patients treated during the same period with autologous HSCT. The median age of patients with allogeneic HSCT at last follow-up was 39 years, and median follow-up was 9 years. Eighteen (6.8%) patients after allogeneic and 3 (2.1%) patients after autologous HSCT experienced an arterial event. The cumulative incidence of first arterial event after allogeneic HSCT was 22.1% (95% CI, 12.0-40.9) at 25 years. The cumulative incidence 15 years after allogeneic HSCT was 7.5% as compared with 2.3% after autologous HSCT. Adjusting for age, risk of an arterial event was significantly higher after allogeneic HSCT (RR 6.92; P =.009). In multivariate analysis, allogeneic HSCT (RR: 14.5; P =.003), and at least 2 of 4 cardiovascular risk factors (hypertension, dyslipidemia, diabetes, obesity) (RR: 12.4; P =.02) were associated with a higher incidence of arterial events after HSCT. Thus, long-term survivors after allogeneic HSCT are at high risk for premature arterial vascular disease. HSCT might favor the emergence of established risk factors, such as hypertension, diabetes, and dyslipidemia.

Entities:  

Mesh:

Year:  2007        PMID: 17664354     DOI: 10.1182/blood-2006-10-054080

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  79 in total

1.  Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation.

Authors:  Nandita Khera; Barry Storer; Mary E D Flowers; Paul A Carpenter; Yoshihiro Inamoto; Brenda M Sandmaier; Paul J Martin; Stephanie J Lee
Journal:  J Clin Oncol       Date:  2011-12-05       Impact factor: 44.544

2.  Changes in echocardiographic measures of systolic and diastolic function in children 1 year after hematopoietic SCT.

Authors:  K P Daly; S D Colan; E D Blume; R Margossian; K Gauvreau; C Duncan; L E Lehmann; M H Chen
Journal:  Bone Marrow Transplant       Date:  2011-01-31       Impact factor: 5.483

3.  Body composition abnormalities in long-term survivors of pediatric hematopoietic stem cell transplantation.

Authors:  Sogol Mostoufi-Moab; Jill P Ginsberg; Nancy Bunin; Babette S Zemel; Justine Shults; Meena Thayu; Mary B Leonard
Journal:  J Pediatr       Date:  2011-08-11       Impact factor: 4.406

4.  Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation.

Authors:  Bradley W Blaser; Haesook T Kim; Edwin P Alyea; Vincent T Ho; Corey Cutler; Philippe Armand; John Koreth; Joseph H Antin; Jorge Plutzky; Robert J Soiffer
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-11       Impact factor: 5.742

5.  Long-term systolic function in children and young adults after hematopoietic stem cell transplant.

Authors:  S J Rotz; C E Dandoy; M D Taylor; S Jodele; J L Jefferies; A Lane; J A El-Bietar; A W Powell; S M Davies; T D Ryan
Journal:  Bone Marrow Transplant       Date:  2017-07-17       Impact factor: 5.483

Review 6.  Vascular Toxicity in Patients with Cancer: Is There a Recipe to Clarify Treatment? CME.

Authors:  Jose Alvarez-Cardona; Joshua Mitchell; Daniel Lenihan
Journal:  Methodist Debakey Cardiovasc J       Date:  2019 Oct-Dec

7.  Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia.

Authors:  Catherine J Lee; Soyoung Kim; Heather R Tecca; Stephanie Bo-Subait; Rachel Phelan; Ruta Brazauskas; David Buchbinder; Betty K Hamilton; Minoo Battiwalla; Navneet S Majhail; Hillard M Lazarus; Peter J Shaw; David I Marks; Mark R Litzow; Saurabh Chhabra; Yoshihiro Inamoto; Zachariah DeFilipp; Gerhard C Hildebrandt; Richard F Olsson; Kimberly A Kasow; Jane L Liesveld; Seth J Rotz; Sherif M Badawy; Neel S Bhatt; Jean A Yared; Kristin M Page; Martha L Arellano; Michael Kent; Nosha Farhadfar; Sachiko Seo; Peiman Hematti; César O Freytes; Alicia Rovó; Siddhartha Ganguly; Sunita Nathan; Linda Burns; Bronwen E Shaw; Lori S Muffly
Journal:  Blood Adv       Date:  2020-03-24

Review 8.  Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up.

Authors:  Smita Bhatia
Journal:  Expert Rev Hematol       Date:  2011-08       Impact factor: 2.929

9.  Late cardiovascular complications after hematopoietic cell transplantation.

Authors:  Eric J Chow; Kenneth Wong; Stephanie J Lee; Kara L Cushing-Haugen; Mary E D Flowers; Debra L Friedman; Wendy M Leisenring; Paul J Martin; Beth A Mueller; K Scott Baker
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-22       Impact factor: 5.742

10.  [Complications after allogeneic bone marrow and stem cell transplantation].

Authors:  E Wollmer; A Neubauer
Journal:  Internist (Berl)       Date:  2014-05       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.